Aptiom is expensive because it’s a brand-name seizure medication with no generic version available in the United States, protected by a wall of patents that extend into the 2030s. A single 800 mg tablet carries a wholesale cost of roughly $20, putting a 30-day supply at around $600 before any insurance or discount programs. That’s many times more than older generic seizure drugs that work through a similar mechanism.
Patent Protection Blocks Generic Competition
The single biggest factor keeping Aptiom’s price high is its patent portfolio. While the original compound patent expired in 2021, Sunovion (the manufacturer) holds additional patents on formulations and manufacturing processes that extend as far as August 2032. The FDA has granted tentative approval to at least one generic version of eslicarbazepine acetate, meaning the agency confirmed the generic meets safety and effectiveness standards. But “tentative” approval doesn’t allow the product to be sold. The generic manufacturer cannot legally bring it to market until the remaining patent protections expire or are successfully challenged.
This is a common strategy in the pharmaceutical industry. Companies file multiple patents covering different aspects of a drug, from the active ingredient itself to the way it’s released in the body, the tablet coating, and the manufacturing method. Each patent creates another barrier that generic manufacturers must either wait out or contest in court. For Aptiom, this layered approach could keep generics off the market for years.
How It Compares to Generic Alternatives
The price gap between Aptiom and older generic seizure medications is striking. Based on formulary cost data, Aptiom runs between $3,500 and $5,200 per year. Compare that to the generics commonly prescribed for the same type of seizures:
- Carbamazepine: $225 to $337 per year
- Lamotrigine: $137 to $675 per year
- Levetiracetam: $397 to $1,098 per year
- Phenytoin: $147 to $294 per year
- Oxcarbazepine: $906 to $2,738 per year
Aptiom costs roughly 10 to 15 times more than carbamazepine, its oldest relative in the same drug family. Even oxcarbazepine, its closest chemical cousin and the most expensive generic on this list, tops out at about half of Aptiom’s annual cost.
What Makes Aptiom Different From Cheaper Options
Aptiom belongs to the same chemical family as carbamazepine and oxcarbazepine. All three drugs work by blocking sodium channels in the brain, which reduces the abnormal electrical activity that causes seizures. So the natural question is: if they work the same way, why does Aptiom exist at all?
The differences are real but incremental. Aptiom is a third-generation version of this drug class, designed to be metabolized more cleanly in the body. Oxcarbazepine gets converted into two mirror-image forms of its active compound, only one of which is primarily responsible for seizure control. Aptiom is converted almost entirely into that preferred form, with very little of the less useful version produced. It also appears to interact with sodium channels in a slightly different way, targeting their slow inactivation state, and may affect a type of calcium channel that the older drugs don’t.
In practical terms, these differences can mean fewer side effects for some patients, particularly the dizziness and nausea that oxcarbazepine is known for. Those side effects are often linked to the peak blood levels of the drug, and Aptiom’s metabolism produces a smoother, more gradual rise. Aptiom can also be taken once daily, while oxcarbazepine typically requires twice-daily dosing. These are meaningful quality-of-life improvements for people who need them, but they don’t represent a fundamentally new treatment, which is part of what makes the price premium frustrating for patients.
The Cost of Developing a “Better” Version
Pharmaceutical companies price brand-name drugs to recoup the cost of clinical trials, regulatory approval, and years of research. Aptiom was approved by the FDA in November 2013 for partial-onset seizures in adults, first as an add-on therapy and later as a standalone treatment. Getting to that point required large-scale trials comparing the drug to placebo and demonstrating its safety profile, a process that typically costs hundreds of millions of dollars.
The pricing also reflects what the market will bear. Sunovion doesn’t just need to cover Aptiom’s own development costs. Pharmaceutical companies use revenue from successful drugs to fund their broader pipeline, including drugs that fail in trials and never reach the market. That business model produces real innovation, but it also means patients on brand-name drugs are effectively subsidizing the company’s entire research operation.
Ways to Lower Your Out-of-Pocket Cost
If you’re taking Aptiom and struggling with the cost, there are several routes worth exploring. Sunovion offers a manufacturer copay card that can significantly reduce what you pay at the pharmacy, though these programs typically require commercial insurance and don’t apply to government plans like Medicare or Medicaid. Patient assistance programs from the manufacturer may provide the drug at no cost to people who meet income requirements.
Your neurologist may also be able to switch you to oxcarbazepine or another generic in the same family, depending on how well you tolerate it. For some people, Aptiom’s smoother side-effect profile is genuinely worth the cost difference. For others, the older generic works just as well. That conversation is worth having, especially if cost is affecting whether you take your medication consistently. Skipping doses of a seizure drug to stretch a prescription is far more dangerous than any difference between these medications.
Until generic eslicarbazepine acetate finally reaches the U.S. market, which hinges on patent expirations stretching into the late 2020s or early 2030s, Aptiom will remain one of the more expensive options in a drug class that otherwise includes very affordable generics.